Walleye Capital
LEGN icon

Walleye Capital’s Legend Biotech LEGN Stock Holding History

Walleye Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$39.7K Buy
+1,995
New +$42.6K ﹤0.01% 5504
2026
Q2 		– Sell
-235,415
Closed -$4.26M – 4987
2026
Q1 		$4.26M Sell
235,415
-64,048
-21% -$1.22M 0.02% 903
2025
Q4 		$6.51M Buy
299,463
+251,037
+518% +$7.19M 0.02% 948
2025
Q3 		$1.58M Buy
48,426
+47,248
+4,011% +$1.74M 0.01% 1755
2025
Q2 		$41.8K Sell
1,178
-72,934
-98% -$2.36M ﹤0.01% 4089
2025
Q1 		$2.51M Sell
74,112
-6,328
-8% -$227K 0.01% 1263
2024
Q4 		$2.62M Buy
80,440
+77,447
+2,588% +$3.21M 0.01% 1532
2024
Q3 		$146K Sell
2,993
-131,985
-98% -$7.03M ﹤0.01% 4207
2024
Q2 		$5.98M Buy
134,978
+132,762
+5,991% +$6.12M 0.01% 1165
2024
Q1 		$124K Buy
+2,216
New +$134K ﹤0.01% 4271

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Triata Capital
Triata Capital Hong Kong $531M AUM 34.32% 1-Year Est. Return
Matthews International Capital Management
Matthews International Capital Management San Francisco, California $241M AUM 42.66% 1-Year Est. Return
Davern Capital Partners
Davern Capital Partners Ny, New York $514M AUM 16.9% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Walleye Capital's LEGN Position: Q3 2026 in Review

Walleye Capital opened a new position in Legend Biotech (LEGN) in Q3 2026: 1,995 shares worth $39.7K. The stake represents ﹤0.01% of the portfolio and ranks #5504 among its holdings. This is a return to the name: Walleye Capital previously reported a position in LEGN as recently as Q1 2026.

Walleye Capital first reported a position in LEGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.51M in Q4 2025. 144 funds tracked by Wall St. Rank hold LEGN as of Q3 2026.

  • Walleye Capital held 1,995 shares of Legend Biotech worth $39.7K as of Q3 2026.
  • Legend Biotech was a new Walleye Capital position in Q3 2026.
  • Legend Biotech made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #5504 holding.
  • Walleye Capital first reported a position in Legend Biotech in Q1 2024 and has held it in 10 quarters since.
  • Walleye Capital's Legend Biotech position peaked at $6.51M in Q4 2025.
  • 144 funds tracked by Wall St. Rank held Legend Biotech as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.